Early emicizumab (Hemlibra) prophylaxis alone prevented clinically relevant bleeds in patients with newly diagnosed acquired hemophilia A, while avoiding the infectious complications of im… Read More
Precision Medicine Market in terms of revenue was estimated to be worth $29.1 billion in 2023 and is poised to reach $50.2 billion by 2028, growing at a CAGR of 11.5 % from 2023 to 2028 acco… Read More
In a world where health is paramount, the pharmaceutical industry stands as a formidable pillar, relentlessly pursuing scientific breakthroughs and life-saving innovations. With each passing… Read More
hemophilia factor deficiency :: Article CreatorAbnormal Uterine Bleeding May Be Caused By Clotting Factor DeficienciesA new review article illuminates why physicians… Read More
hemophilia genetic disorder :: Article CreatorBioMarin's Next Roctavian Challenge Is How To Successfully Commercialize Its Gene Therapy: Warranties May Be An Option… Read More
It’s been a big week for cell and gene therapy approvals in the US, including a much-awaited approval for one to treat hemophilia A, the most common form of hemophilia. The US Food and… Read More
Haemophilia is a rare condition in which the blood does not clot normally due to a lack of blood-clotting proteins (clotting factors). If you have hemophilia, you may bleed more profusely an… Read More
By Ludwig Burger
BASEL (Reuters) – Roche warned of a decline in 2023 earnings, as revenue growth from new drugs, including its haemophilia treatment and multiple sclerosis drug, would… Read More
Bharat Book Bureau Provides the Trending Market Research Report on “Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028” under the… Read More
The hemophilia A gene therapy Roctavian delivers a functional gene to enable the body to make an essential blood clotting protein on its own.
Hemophilia is a rare bleeding disorder where the… Read More
HEMLIBRA ® (emicizumab-kxwh) injection https://gafacom.website/hemlibra-emicizumab-kxwh-injection/ MedicinesHEMLIBRA is a bispecific factor IXa- and factor X-directed antibody indicate… Read More
Every one of us hates standing in long queues and waiting for our turn to buy medicines in the pharmacy stores. Sometimes customers get disappointed if the stocks of medicine are less, it is… Read More
2020 was a year of COVID-19’s wreak havoc, and also a year of rapid growth in biomedicine. We recorded the development of the industry news.
Popular targets
PD-1
Although PD-1… Read More
In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple scle… Read More
Single User License: 5,195 USD Multi User License: 8,195 USDCorporate License: 11,195 USD
Buy Now
Request Sample
Request Customization
Global Hemophilia… Read More
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced yesterday that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA… Read More